Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT02383433
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 123
- Registration Number
- NCT02368886
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 78
- Registration Number
- NCT02365441
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Flinders Medical Centre, Adelaide, South Australia, Australia
🇦🇺Sir Charles Gairdner, Perth, Western Australia, Australia
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 42
- Registration Number
- NCT02316340
- Locations
- 🇺🇸
Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting
- Conditions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 704
- Registration Number
- NCT02310477
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Istituto Clinico Humanitas
- Target Recruit Count
- 82
- Registration Number
- NCT02307500
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
- Conditions
- Interventions
- Other: General conditionOther: Blood pressureOther: Patient Reported OutcomeOther: Clinical findingsOther: Hematology/blood chemistryOther: Coagulation and fibrinolysis systemOther: UrinalysisOther: Medication checkOther: Adverse eventOther: Thyroid function testOther: Contrast-enhanced torso CTOther: Brain MRIDrug: DexamethasoneDrug: PlaceboDrug: RegorafenibDrug: Proton pump inhibitor
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Clinical Research Support Center Kyush
- Target Recruit Count
- 74
- Registration Number
- NCT02288078
- Locations
- 🇯🇵
Saiseikai Fukuoka General Hospital, Fukuoka, Japan
Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT02287727
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Rochester Medical Center - Wilmont Cancer Institute, Rocherster, New York, United States
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 1
- Registration Number
- NCT02278783
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 3
- Registration Number
- NCT02259725
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.